Glaukos Publishes Q3 2026 Earnings Call Transcript
Bitget2026/10/29 23:17- Glaukos raised 2026 net sales guidance to $775 million-$785 million from $680 million-$700 million.
- Preliminary 2027 revenue guidance reached $1 billion, factoring in potential restrictive Medicare coverage decisions for iDose TR.
- Third-quarter net sales rose 58% to a record $211 million.
- Epioxa contributed approximately $53 million in sales; iDose TR generated approximately $76 million.
- The October 28, 2026 earnings call featured CEO Thomas William Burns, COO Joseph E. Gilliam and CFO Alex R. Thurman.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: AI capital expenditure may reach 10 to 15 trillions USD in the next 10 years
Morgan Stanley stated that capital expenditure in the artificial intelligence (AI) sector could reach $10-15 trillions over the next decade.
Morgan Stanley: Apple's target price lowered to $350
Autoliv completes acquisition of MCF Safety Belts
Refining profits surge and oil prices soar; Saudi Aramco Q3 profits grow by 9% and maintains a dividend of 21.9 billions USD.
Driven by rising refining profits and oil prices, Saudi Aramco's third-quarter profits increased by 9%.
Crypto prices
More
